San Francisco, CA--
Paul Hastings LLP, a leading global law firm, announced today that it represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of $375,000,000 aggregate principal amount of its 0.75% Senior Subordinated Convertible Notes due 2018 and $375,000,000 aggregate principal amount of its 1.50% Senior Subordinated Convertible Notes due 2020.
BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Barclays acted as co-manager for the offering.
In connection with the pricing of the offering and the exercise in full of their overallotment option by the underwriters, BioMarin entered into privately-negotiated capped call transactions with Bank of America, N.A., Morgan Stanley & Co. LLC and Barclays Bank PLC in respect of 50% of the principal amount of the notes.
Securities & Capital Markets partner Thomas Pollock
led the Paul Hastings team, which also included partners Robert Claassen
, Michael Zuppone
, Leigh Ryan
and Andrew Short
and associates Sasha Burstein
, Peiyi Zhao
, Christy Chen
, Aliza Cohen
, Daniel Greenwald
and Kaethin Prizer.
Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.